Arena Pharmaceuticals

Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors (GPCRs) to address unmet medical needs. The Company’s most advanced investigational clinical programs are ralinepag (formerly APD811) in testing for pulmonary arterial hypertension (PAH), etrasimod (formerly APD334) in evaluation for inflammatory indications and APD371 for the treatment of pain associated with Crohn’s disease.

Company Growth (employees)
Type
Public
HQ
San Diego, US
Founded
1977
Size (employees)
106 (est)-53%
Arena Pharmaceuticals was founded in 1977 and is headquartered in San Diego, US

Arena Pharmaceuticals Office Locations

Arena Pharmaceuticals has offices in San Diego and Zofingen
San Diego, US (HQ)
6154 Nancy Ridge Drive
Zofingen, CH
4 Untere Brühlstrasse

Arena Pharmaceuticals Financials and Metrics

Arena Pharmaceuticals Financials

Arena Pharmaceuticals's revenue was reported to be $6.6 m in Q1, 2017
USD

Revenue (Q1, 2017)

6.6 m

Gross profit (Q1, 2017)

4.1 m

Gross profit margin (Q1, 2017), %

62%

Net income (Q1, 2017)

(22.5 m)

EBIT (Q1, 2017)

(20.5 m)

Market capitalization (12-Oct-2017)

791.1 m

Cash (31-Mar-2017)

79.5 m
Arena Pharmaceuticals's current market capitalization is $791.1 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

81.4 m37 m38.3 m124 m

Revenue growth, %

(55%)4%223%

Cost of goods sold

1.8 m6.4 m8.6 m9.3 m

Gross profit

79.6 m30.6 m29.7 m114.7 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

12.8 m8.2 m12.3 m9.2 m9.1 m9.8 m9.5 m19.2 m6.6 m

Cost of goods sold

1.5 m1.8 m3.2 m1.3 m1.6 m2.4 m851 k882 k2.5 m

Gross profit

11.3 m6.4 m9.1 m7.9 m7.5 m7.4 m8.7 m18.4 m4.1 m

Gross profit Margin, %

89%79%74%86%82%75%91%95%62%
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

221.9 m163.2 m156.2 m90.7 m

Accounts Receivable

10.6 m3.7 m4.9 m20.2 m

Inventories

3.6 m4.1 m4.2 m6.7 m

Current Assets

248.8 m181.9 m174.8 m119.9 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

200.8 m188.3 m241 m216.7 m181.3 m139.5 m122 m101.6 m79.5 m

Accounts Receivable

7.4 m2.9 m12.2 m4.2 m3.5 m6.2 m3.3 m18.3 m1.7 m

Inventories

12.6 m11.9 m11.4 m11 m10.2 m9.1 m9.5 m10.2 m7.1 m

Current Assets

243.7 m209.1 m268.6 m236 m200.2 m160.1 m139.8 m134.9 m92.3 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(19.4 m)(60.5 m)(108 m)(22.9 m)

Depreciation and Amortization

7.7 m8.7 m9.8 m9.1 m

Accounts Receivable

(4.5 m)6.4 m(1.4 m)(15.9 m)

Inventories

(6.1 m)870 k1.9 m3.2 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

7.5 m(10.7 m)(24.3 m)(26.8 m)(26.4 m)(21.5 m)(27.2 m)(12.5 m)(22.5 m)

Accounts Receivable

7.4 m2.9 m12.2 m4.2 m3.5 m6.2 m3.3 m18.3 m1.7 m

Inventories

12.6 m11.9 m11.4 m11 m10.2 m9.1 m9.5 m10.2 m7.1 m
USDY, 2017

Revenue/Employee

39.7 k

Financial Leverage

5.2 x
Show all financial metrics

Arena Pharmaceuticals Market Value History

Traffic Overview of Arena Pharmaceuticals

Arena Pharmaceuticals Company Life and Culture

You may also be interested in